Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 3/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096214 | 0.87 | AS3MT (0.53) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL13152663 | 0.85 | AR (0.54) | RAB9ASMN1; SMN2DYRK1AMEN1NPC1 | |
| SCHEMBL13152382 | 0.85 | AR (0.55) | RAB9ASMN1; SMN2DYRK1AAS3MTPLK1 | |
| SCHEMBL12950256 | 0.84 | AR (0.52) | RAB9AGAAMAPTSMN1; SMN2DYRK1A | |
| SCHEMBL13214446 | 0.83 | ALDH1A1 (0.46) | RAB9AMAPTSMN1; SMN2MEN1NPC1 | |
| SCHEMBL13152348 | 0.82 | MAOB (0.49) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL10097698 | 0.82 | AR (0.41) | RAB9ASMN1; SMN2DYRK1AMEN1NPC1 | |
| SCHEMBL13151779 | 0.81 | MAOB (0.48) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL13151799 | 0.81 | AS3MT (0.58) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL13152630 | 0.78 | AR (0.55) | MAOBRAB9ASMN1; SMN2AS3MTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAOB 4153/4885RAB9A 2829/4885GAA 667/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MAOB 1255/4885RAB9A 2969/4885GAA 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.